Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20817410 | 0.86 | PDE4B (0.43) | GPBAR1ALDH1A1NR1H4TP53 | |
| SCHEMBL497932 | 0.81 | NPSR1 (0.45) | ALDH1A1NPSR1NR4A2TP53HTT | |
| SCHEMBL19810784 | 0.78 | NR1H4 (0.42) | ALDH1A1NR1H4NPSR1NR4A2TP53 | |
| SCHEMBL20962531 | 0.78 | NR1H4 (0.37) | GPBAR1ALDH1A1NR1H4NPC1RAB9A | |
| SCHEMBL20952033 | 0.74 | NR1H4 (0.36) | GPBAR1ALDH1A1NR1H4NPC1RAB9A | |
| SCHEMBL498171 | 0.73 | NR1H4 (0.44) | GPBAR1ALDH1A1NR1H4NPC1RAB9A | |
| SCHEMBL20817390 | 0.71 | NR1H4 (0.43) | GPBAR1ALDH1A1NR1H4NPC1RAB9A | |
| SCHEMBL22392841 | 0.71 | NR1H4 (0.43) | GPBAR1ALDH1A1NR1H4NPC1RAB9A | |
| SCHEMBL1097054 | 0.70 | NR1H4 (0.42) | GPBAR1ALDH1A1NR1H4NPC1RAB9A | |
| SCHEMBL22407512 | 0.69 | NR1H4 (0.41) | GPBAR1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | GPBAR1 5/4885SLC6A3 3051/4885ALDH1A1 2294/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | GPBAR1 5/4885SLC6A3 3530/4885ALDH1A1 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.